Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Garber, Alan, Henry, Robert, Ratner, Robert · The Lancet · 2009